Artificial intelligence could enhance how tumor samples are analyzed in the lab—significantly improving how doctors determine the best treatment for cancer patients, a study by researchers at the Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center, and other collaborators suggests.
Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.
